PortalPublikationenAnxiolytic activity of atrial natriuretic peptide in patient...

Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.

Standard

Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. / Ströhle, A; Kellner, M; Holsboer, F; Wiedemann, Klaus.

in: AM J PSYCHIAT, Jahrgang 158, Nr. 9, 9, 2001, S. 1514-1516.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ströhle, A, Kellner, M, Holsboer, F & Wiedemann, K 2001, 'Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.', AM J PSYCHIAT, Jg. 158, Nr. 9, 9, S. 1514-1516. <http://www.ncbi.nlm.nih.gov/pubmed/11532742?dopt=Citation>

APA

Ströhle, A., Kellner, M., Holsboer, F., & Wiedemann, K. (2001). Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. AM J PSYCHIAT, 158(9), 1514-1516. [9]. http://www.ncbi.nlm.nih.gov/pubmed/11532742?dopt=Citation

Vancouver

Ströhle A, Kellner M, Holsboer F, Wiedemann K. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. AM J PSYCHIAT. 2001;158(9):1514-1516. 9.

Bibtex

@article{e0580c748afd4a5095015364d1aaa73a,
title = "Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.",
abstract = "OBJECTIVE: Preclinical evidence exists for the anxiolytic activity of atrial natriuretic peptide, which is released during lactate-induced panic attacks. Atrial natriuretic peptide receptor modulation may have antipanic activity in patients with panic disorder. METHOD: The effects of 150 microg of atrial natriuretic peptide and placebo on panic attacks induced by cholecystokinin tetrapeptide (CCK-4) (25 microg) were studied in 10 panic disorder patients. The panicogenic activity of CCK-4 was measured with the Acute Panic Inventory. RESULTS: Panic attacks occurred in seven patients in the placebo condition and in two patients in the atrial natriuretic peptide condition. CCK-4 administration was accompanied by a significant increase in Acute Panic Inventory scores. Pretreatment with atrial natriuretic peptide resulted in significantly lower Acute Panic Inventory scores than pretreatment with placebo. CONCLUSIONS: The results support the antipanic activity of atrial natriuretic peptide. Nonpeptidergic atrial natriuretic peptide receptor ligands may be ultimately used to treat anxiety disorders.",
author = "A Str{\"o}hle and M Kellner and F Holsboer and Klaus Wiedemann",
year = "2001",
language = "Deutsch",
volume = "158",
pages = "1514--1516",
journal = "AM J PSYCHIAT",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "9",

}

RIS

TY - JOUR

T1 - Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.

AU - Ströhle, A

AU - Kellner, M

AU - Holsboer, F

AU - Wiedemann, Klaus

PY - 2001

Y1 - 2001

N2 - OBJECTIVE: Preclinical evidence exists for the anxiolytic activity of atrial natriuretic peptide, which is released during lactate-induced panic attacks. Atrial natriuretic peptide receptor modulation may have antipanic activity in patients with panic disorder. METHOD: The effects of 150 microg of atrial natriuretic peptide and placebo on panic attacks induced by cholecystokinin tetrapeptide (CCK-4) (25 microg) were studied in 10 panic disorder patients. The panicogenic activity of CCK-4 was measured with the Acute Panic Inventory. RESULTS: Panic attacks occurred in seven patients in the placebo condition and in two patients in the atrial natriuretic peptide condition. CCK-4 administration was accompanied by a significant increase in Acute Panic Inventory scores. Pretreatment with atrial natriuretic peptide resulted in significantly lower Acute Panic Inventory scores than pretreatment with placebo. CONCLUSIONS: The results support the antipanic activity of atrial natriuretic peptide. Nonpeptidergic atrial natriuretic peptide receptor ligands may be ultimately used to treat anxiety disorders.

AB - OBJECTIVE: Preclinical evidence exists for the anxiolytic activity of atrial natriuretic peptide, which is released during lactate-induced panic attacks. Atrial natriuretic peptide receptor modulation may have antipanic activity in patients with panic disorder. METHOD: The effects of 150 microg of atrial natriuretic peptide and placebo on panic attacks induced by cholecystokinin tetrapeptide (CCK-4) (25 microg) were studied in 10 panic disorder patients. The panicogenic activity of CCK-4 was measured with the Acute Panic Inventory. RESULTS: Panic attacks occurred in seven patients in the placebo condition and in two patients in the atrial natriuretic peptide condition. CCK-4 administration was accompanied by a significant increase in Acute Panic Inventory scores. Pretreatment with atrial natriuretic peptide resulted in significantly lower Acute Panic Inventory scores than pretreatment with placebo. CONCLUSIONS: The results support the antipanic activity of atrial natriuretic peptide. Nonpeptidergic atrial natriuretic peptide receptor ligands may be ultimately used to treat anxiety disorders.

M3 - SCORING: Zeitschriftenaufsatz

VL - 158

SP - 1514

EP - 1516

JO - AM J PSYCHIAT

JF - AM J PSYCHIAT

SN - 0002-953X

IS - 9

M1 - 9

ER -